Remimazolam Tosilate for Injection
Pre-clinicalCompleted 0 watching 0 views this week๐ค Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
General Anesthesia and Bronchoscopy Sedation
Conditions
General Anesthesia and Bronchoscopy Sedation
Trial Timeline
Aug 18, 2022 โ Jun 21, 2024
NCT ID
NCT05549791About Remimazolam Tosilate for Injection
Remimazolam Tosilate for Injection is a pre-clinical stage product being developed by Jiangsu Hengrui Medicine for General Anesthesia and Bronchoscopy Sedation. The current trial status is completed. This product is registered under clinical trial identifier NCT05549791. Target conditions include General Anesthesia and Bronchoscopy Sedation.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05549791 | Pre-clinical | Completed |
| NCT05254366 | Pre-clinical | Completed |
Competing Products
20 competing products in General Anesthesia and Bronchoscopy Sedation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 65 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Perampanel + Placebo comparator | Eisai | Phase 3 | 77 |
| zonisamide | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Perampanel | Eisai | Phase 3 | 77 |
| Perampanel | Eisai | Pre-clinical | 23 |
| Cenobamate | Ono Pharmaceutical | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Approved | 85 |
| Ixekizumab | Eli Lilly | Approved | 85 |
| eszopiclone + eszopiclone + Placebo | Sumitomo Pharma | Phase 2 | 52 |
| Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment | Sumitomo Pharma | Approved | 85 |
| HR020602 injection + fentanyl injection ๏ผ remifentanil injection | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Remimazolam Tosilate + Propofol | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT) | AbbVie | Phase 2 | 52 |
| Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day | AbbVie | Phase 2 | 52 |
| ABBV-932 + Placebo | AbbVie | Phase 1 | 33 |